Last reviewed · How we verify
oxaliplatin and ON 01910.Na
At a glance
| Generic name | oxaliplatin and ON 01910.Na |
|---|---|
| Also known as | Eloxatin, oxaloplatinum, oxalatoplatin, rigosertib sodium |
| Sponsor | Traws Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin (PHASE1)
- Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oxaliplatin and ON 01910.Na CI brief — competitive landscape report
- oxaliplatin and ON 01910.Na updates RSS · CI watch RSS
- Traws Pharma, Inc. portfolio CI